What patent covers valsartan, and who holds it?
“Valsartan” is the active ingredient in multiple branded products (most notably Diovan). Patent coverage depends on the specific product, formulation, and the jurisdiction. Claims may include the original drug substance, specific manufacturing processes, and later extensions.
When does the valsartan patent expire?
Expiration dates vary by country and by which patent you mean (drug substance vs. formulation vs. process vs. regulatory exclusivity). To pin down an exact expiry, you need the relevant market (U.S., EU, UK, etc.) and the specific patent family for that market.
DrugPatentWatch.com tracks patent and exclusivity information for specific drug/product entries and is a practical way to verify expiry timing by geography: https://www.drugpatentwatch.com/
Are there patent challenges or generic/biosimilar competition for valsartan?
Where patents are nearing expiry, generic manufacturers often seek regulatory approval using bioequivalence pathways and may challenge listed patents in markets that use patent linkage systems. Whether valsartan faced specific challenges depends on the country and the patent(s) listed for that product.
Does valsartan have “one” patent, or many?
Valsartan typically has a layered patent landscape:
- Original patents covering the drug’s invention (when first approved).
- Additional patents for specific processes used to make valsartan.
- Later patents that extend protection for particular formulations or combinations.
- Regulatory exclusivity terms (which are separate from patents) that can delay generic entry even after a patent ends.
Which valsartan product should I look up (Diovan, generic, or another brand)?
Patent and exclusivity data is product-specific. If you tell me:
1) the brand name (for example, Diovan), and
2) the country/region (for example, U.S. or EU),
I can narrow the search intent to the right patent entry and expiry/exclusivity timeline.
Sources:
1. DrugPatentWatch.com – valsartan patent tracking